BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer

  • Park, JaeIn (Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University) ;
  • Jang, Jae-Hyun (Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University) ;
  • Park, Geun-Soo (Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University) ;
  • Chung, Yunro (Department of Biomedical Informatics, Arizona State University) ;
  • You, Hye Jin (Translational Research Branch, Division of Translational Science, National Cancer Center) ;
  • Kim, Jae-Hong (Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University)
  • Received : 2018.05.20
  • Published : 2018.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity $LTB_4$ receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC.

Keywords

References

  1. Anders CK, Winer EP, Ford JM et al (2010) Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res 16, 4702-4710 https://doi.org/10.1158/1078-0432.CCR-10-0939
  2. Carey L, Winer E, Viale G, Cameron D and Gianni L (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7, 683-692 https://doi.org/10.1038/nrclinonc.2010.154
  3. Kassam F, Enright K, Dent R et al (2009) Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 9, 29-33 https://doi.org/10.3816/CBC.2009.n.005
  4. Dinarello CA (2006) The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev 25, 307-313 https://doi.org/10.1007/s10555-006-9000-8
  5. Tager AM and Luster AD (2003) BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids 69, 123-134 https://doi.org/10.1016/S0952-3278(03)00073-5
  6. Park GS and Kim JH (2015) Myeloid differentiation primary response gene 88-leukotriene B4 receptor 2 cascade mediates lipopolysaccharide-potentiated invasiveness of breast cancer cells. Oncotarget 6, 5749-5759
  7. Maiello MR, D'Alessio A, Bevilacqua S, Gallo M, Normanno N and De Luca A (2015) EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. J Cell Biochem 116, 2778-2785 https://doi.org/10.1002/jcb.25220
  8. Lonne GK, Masoumi KC, Lennartsson J and Larsson C (2009) Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway. J Biol Chem 284, 33456-33465 https://doi.org/10.1074/jbc.M109.036186
  9. Bogucki DJ and Domaradzki JA (2005) Numerical study of light scattering by a boundary-layer flow. Appl Opt 44, 5286-5291 https://doi.org/10.1364/AO.44.005286
  10. Weng MS, Chang JH, Hung WY, Yang YC and Chien MH (2018) The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance. J Exp Clin Cancer Res 37, 61 https://doi.org/10.1186/s13046-018-0728-0
  11. Pelicano H, Zhang W, Liu J et al (2014) Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Breast Cancer Res 16, 434 https://doi.org/10.1186/s13058-014-0434-6
  12. Puca R, Nardinocchi L, Starace G et al (2010) Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis. Free Radic Biol Med 48, 1338-1346 https://doi.org/10.1016/j.freeradbiomed.2010.02.015
  13. Choi JA, Lee JW, Kim H et al (2010) Pro-survival of estrogen receptor-negative breast cancer cells is regulated by a BLT2-reactive oxygen species-linked signaling pathway. Carcinogenesis 31, 543-551 https://doi.org/10.1093/carcin/bgp203
  14. Blot E, Chen W, Vasse M et al (2003) Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness. Br J Cancer 88, 1207-1212 https://doi.org/10.1038/sj.bjc.6600872
  15. Chittezhath M, Dhillon MK, Lim JY et al (2014) Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity 41, 815-829 https://doi.org/10.1016/j.immuni.2014.09.014
  16. Nakasone ES, Hurvitz SA and McCann KE (2018) Harnessing the immune system in the battle against breast cancer. Drugs Context 7, 212520
  17. Brown EJ (1997) Adhesive interactions in the immune system. Trends Cell Biol 7, 289-295 https://doi.org/10.1016/S0962-8924(97)01076-3
  18. Ohene-Abuakwa Y and Pignatelli M (2000) Adhesion molecules as diagnostic tools in tumor pathology. Int J Surg Pathol 8, 191-200 https://doi.org/10.1177/106689690000800306
  19. Zhong L, Simard MJ and Huot J (2018) Endothelial microRNAs regulating the NF-kappaB pathway and cell adhesion molecules during inflammation. FASEB J, fj201701536R
  20. Hubbard AK and Rothlein R (2000) Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radic Biol Med 28, 1379-1386 https://doi.org/10.1016/S0891-5849(00)00223-9
  21. Evani SJ, Prabhu RG, Gnanaruban V, Finol EA and Ramasubramanian AK (2013) Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow. FASEB J 27, 3017-3029 https://doi.org/10.1096/fj.12-224824
  22. Rosette C, Roth RB, Oeth P et al (2005) Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 26, 943-950 https://doi.org/10.1093/carcin/bgi070
  23. Strell C, Lang K, Niggemann B, Zaenker KS and Entschladen F (2010) Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1. Exp Cell Res 316, 138-148 https://doi.org/10.1016/j.yexcr.2009.09.003
  24. Schroder C, Witzel I, Muller V et al (2011) Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J Cancer Res Clin Oncol 137, 1193-1201 https://doi.org/10.1007/s00432-011-0984-2
  25. Park GS and Kim JH (2015) LPS Up-Regulates ICAM-1 expression in breast cancer cells by stimulating a MyD88-BLT2-ERK-Linked cascade, which promotes adhesion to monocytes. Mol Cells 38, 821-828 https://doi.org/10.14348/molcells.2015.0174
  26. Neophytou C, Boutsikos P and Papageorgis P (2018) Molecular mechanisms and emerging therapeutic targets of triple-negative breast cancer metastasis. Front Oncol 8, 31 https://doi.org/10.3389/fonc.2018.00031
  27. Christofori G (2006) New signals from the invasive front. Nature 441, 444-450 https://doi.org/10.1038/nature04872
  28. Liang Z, Bian X and Shim H (2016) Downregulation of microRNA-206 promotes invasion and angiogenesis of triple negative breast cancer. Biochem Biophys Res Commun 477, 461-466 https://doi.org/10.1016/j.bbrc.2016.06.076
  29. Ma Y, Ren Y, Dai ZJ, Wu CJ, Ji YH and Xu J (2017) IL-6, IL-8 and TNF-alpha levels correlate with disease stage in breast cancer patients. Adv Clin Exp Med 26, 421-426 https://doi.org/10.17219/acem/62120
  30. Hartman ZC, Poage GM, den Hollander P et al (2013) Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 73, 3470-3480 https://doi.org/10.1158/0008-5472.CAN-12-4524-T
  31. De Larco JE, Wuertz BR, Rosner KA et al (2001) A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 158, 639-646 https://doi.org/10.1016/S0002-9440(10)64005-9
  32. Kim H, Choi JA, Park GS and Kim JH (2012) BLT2 up-regulates interleukin-8 production and promotes the invasiveness of breast cancer cells. PLoS One 7, e49186 https://doi.org/10.1371/journal.pone.0049186
  33. Madden SF, Clarke C, Gaule P et al (2013) BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res 15, R52 https://doi.org/10.1186/bcr3444
  34. Connolly C, Madden SF, Buggy DJ and Gallagher HC (2017) Expression of anaesthetic and analgesic drug target genes in excised breast tumour tissue: Association with clinical disease recurrence or metastasis. PLoS One 12, e0177105 https://doi.org/10.1371/journal.pone.0177105
  35. Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1
  36. Lavigne AC, Castells M, Mermet J, Kocanova S, Dalvai M and Bystricky K (2014) Increased macroH2A1.1 expression correlates with poor survival of triple-negative breast cancer patients. PLoS One 9, e98930 https://doi.org/10.1371/journal.pone.0098930